Compare Abeona Therapeutics Inc (ABEO) vs Google Inc (GOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Google Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Google Inc trades at $341.25 (market cap $4.20T). The key difference: Google Inc is far larger — about 9971.7× Abeona Therapeutics Inc's market cap, and Google Inc pays a 0.26% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GOOG | |
|---|---|---|
Market Cap | $421.19M | $4.20T |
Sector | Health | Technology |
52-Week High | $7.45 | $399.06 |
52-Week Low | $4.17 | $200.19 |
Enterprise Value | $276.10M | $4.09T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Alphabet (GOOG) trades at $355.84, up 0.67% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $402.84 billion in 2025, with net income surging to $132.17 billion, and announced a new AI leadership structure to accelerate Gemini development amid rising user adoption.
Outlook remains positive with an 86.84% analyst buy rating and a $431.67 consensus price target, though risks include high capital expenditure for AI infrastructure and regulatory scrutiny. The stock offers growth potential from AI monetization but faces volatility from tech sector pressures and antitrust investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
